A retrospective, multicenter study of baseline characteristics, dosage, and platelet endpoints after initiation of romiplostim in newly diagnosed, persistent and chronic immune thrombocytopenia patients
Latest Information Update: 06 Aug 2021
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
Most Recent Events
- 06 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association